Here are five highlights:
1. Misonix’s net sales for the second quarter 2016 reached $6 million, compared to $5.6 million for the same period last year.
2. The BoneScalpel global revenue increased 8 percent to $3.2 million, and U.S. revenue increased 13 percent to $1.9 million.
3. In the United States, the company sold 35 BoneScalpel units in the second quarter, compared to 27 in the same period last year.
4. SonicOneOR global revenue increased 64 percent to $745,000 in the second quarter.
5. Recurring revenue of BoneScalpel, SonaStar and SonicOne disposable sales increased to $3.8 million.
More articles on devices:
Spine surgery reimbursement: Key thoughts on coverage for new technology
Stryker buys Synergetics’ neuro portfolio on the heels of Sage acquisition: 5 key notes
NuVasive establishes new 52-week low: 4 points
